Current Report Filing (8-k)

Date : 12/14/2018 @ 10:10PM
Source : Edgar (US Regulatory)
Stock : Marizyme, Inc. (MRZM)
Quote : 1.01  0.0 (0.00%) @ 8:59PM

Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 14, 2018 (December 12, 2018)

 

 

MARIZYME, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

000-27237

 

82-5464863

(State or other jurisdiction
of incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

2950 E. Harmony Rd., Suite 255, Fort Collins, CO 80528

 

80528

(Address of principal executive offices)

 

(Zip Code)

 

(925) 400-3123

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[   ]

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[   ]

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[   ]

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[   ]

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging Growth Company   [X]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

[   ]



ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

 

Resignation of Director and Officer

 

On December 12, 2018, Juan Francisco Gutierrez resigned as a member of the board of directors of Marizyme, Inc. (the “Company”). Mr. Gutierrez’s resignation was not in connection with any known disagreement with the Company on any matter.

 

On the same date, Marco Nicolaides resigned as the Company’s Treasurer.

 

Appointment of Directors

 

On December 12, 2018, the board of directors of the Company increased the size of the board from two to three members and appointed James Sapirstein and Terry Brostowin to the board to fill the vacancies created by Mr. Gutierrez’s resignation and such increase. Mr. Sapirstein was also appointed as Executive Chairman.

 

James Sapirstein, age 57, is a highly-regarded pharmaceutical industry executive with more than 35 years of success in building companies and leading the commercial launch of nearly two dozen prescription drugs in the fields of CNS, infectious disease, and cancer. He has worked at major pharmaceutical companies including Bristol-Myers Squibb, Hoffmann-LaRoche and Eli Lilly, and has led commercial teams for successful biotech companies such as Gilead Sciences and Serono Laboratories. In recent years, Mr. Sapirstein has been the founding CEO of the following early-stage biotech companies - Tobira Therapeutics (NASDAQ:TBRA) from 2006 to 2011, Alliqua Therapeutics (NASDAQ:ALQA) from 2012 to 2014, and most recently, Contravir Pharmaceuticals (NASDAQ:CTRV), from 2014 to 2018, where he defined and executed corporate strategy, raised significant capital, advanced drug development programs, and built shareholder value.

 

Terry Brostowin, age 59, is an accomplished attorney admitted to the Federal Court in both the Eastern and Southern districts of New York. He has extensive expertise in contracts, and commercial litigation. Mr. Brostowin has advised the New York City Mayor’s office on judicial appointments and was a compliance specialist ensuring agencies followed court ordered activities and ensured the financial integrity of the Financial Systems Division accounting and budgetary systems. Mr. Brostowin has been affiliated with the law firm Brostowin & Associates, PC, since 2009. From 2002 to 2009, Mr. Brostowin was affiliated with the law firm Conway & Brostowin, LLC.

 

The newly appointed directors were appointed until their successors are duly elected and qualified. There are no arrangements or understandings between the newly appointed directors and any other persons pursuant to which they were selected as directors. There are no family relationships among the newly appointed directors and our directors or officers. There has been no transaction, nor is there any currently proposed transaction, between any newly appointed director and the Company that would require disclosure under Item 404(a) of Regulation S-K.

 

ITEM 8.01. Other Events  

 

On December 14, 2018, the Company issued a press release announcing the board of directors changes. The press release is attached hereto as Exhibit 99.1 and is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, or the Exchange Act, except as expressly set forth by specific reference in any such filings.

 

ITEM 9.01. Financial Statement and Exhibits  

 

(d) Exhibits

 

The following exhibits are filed herewith:

 

Exhibit No.

 

Description of Exhibit

99.1

 

Press Release of the Registrant dated December 14, 2018 relating to the Appointment of New Members of the Board of Directors


 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Marizyme, Inc. has duly caused this current report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: December 14, 2018

MARIZYME, INC.

 

 

 

 

By:

/s/ Michael K. Handley

 

 

Michael K. Handley

 

 

Chief Executive Officer

 

 

 

Marizyme, Inc. (USOTC:MRZM)
Historical Stock Chart

1 Year : From Jun 2018 to Jun 2019

Click Here for more Marizyme, Inc. Charts.

Marizyme, Inc. (USOTC:MRZM)
Intraday Stock Chart

Today : Monday 17 June 2019

Click Here for more Marizyme, Inc. Charts.

Latest MRZM Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.